Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global pandemic, which is associated with venous thromboembolism and pulmonary embolism (PE). This study aimed to estimate the pooled incidence of PE among patients hospitalized with COVID-19 within the published literature. Methods: This systematic review and meta-analysis was performed according to PRISMA guidelines. An electronic search using MEDLINE /PubMed, ScienceDirect, Cochrane, and OpenGray databases was conducted May 19th, 2020. Eligible studies included sufficient data to calculate the incidence of PE diagnosed during hospitalization in patients with COVID-19. Case reports were excluded. Quality was assessed using the Newcastle-Ottawa scale (observational cohort and case-control), AXIS tool (cross-sectional), and quality assessment tool (case series). Demographics and PE incidence data were extracted from the included studies and analyzed with R language. The pooled incidence of PE in patients hospitalized with COVID-19 was calculated. Results: The database search identified 128 records. Ten observational studies were eligible and were included in the meta-analysis with a total of 1722 patients (mean age= 63.36). .The incidence of PE was noted to be higher in males. The D-dimer levels were specified between PE group and non-PE group in only three studies, while the remaining either reported it improperly or had missing data.The pooled PE incidence in patients hospitalized with COVID-19 was 17% (95% CI: 0.1-0.26). There was a high degree of study heterogeneity (I2 = 94%, p<0.01). Conclusion: The pooled PE incidence in patients hospitalized with COVID-19 is 17%. This increased incidence is greater than that previously reported in the general population of non-COVID-19. Attention and further investigation of this risk is warranted.
Highlights
In December 2019, pneumonia of unknown cause was detected in Wuhan, China1
Thromboembolism has been previously associated with zoonotic coronaviruses6 and may be attributed to several factors including; a hypercoagulable state associated with severe infection or inflammation7, COVID-19 associated hemostatic abnormalities8,9, recumbence7,10–12, and possible drug interactions between investigational COVID-19 therapies (Lopinavir/ritonavir) and antithrombotics5
PubMed, Cochrane, and OpenGrey were queried for the following strategy: (“COVID 19” OR “SARS-CoV-2” OR “coronavirus disease 2019” OR “2019-nCoV” OR “Wuhan coronavirus”) AND (“Pulmonary embolism” OR “pulmonary thromboembolism” OR “Pulmonary embol*” OR “pulmonary thrombo*” OR “pulmonary embolism (PE)”)
Summary
In December 2019, pneumonia of unknown cause was detected in Wuhan, China. The causative agent was identified and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On March 11th, 2020, the World Health Organization characterized the coronavirus disease of 2019 (COVID-19) as a pandemic, resulting in 53,507,282 and 1,305,164 COVID-19-related cases and deaths, respectively, as of November 15th, 20204. While COVID-19 is primarily a pulmonary disease, there are multiple other pathologic manifestations and complications, including pulmonary embolism (PE). Thromboembolism has been previously associated with zoonotic coronaviruses and may be attributed to several factors including; a hypercoagulable state associated with severe infection or inflammation, COVID-19 associated hemostatic abnormalities, recumbence, and possible drug interactions between investigational COVID-19 therapies (Lopinavir/ritonavir) and antithrombotics. Coronavirus disease 2019 (COVID-19) is a global pandemic, which is associated with venous thromboembolism and pulmonary embolism (PE). This study aimed to estimate the pooled incidence of PE among patients hospitalized with COVID-19 within the published literature. Eligible studies included sufficient data to calculate the incidence of PE diagnosed during hospitalization in patients with COVID-19. Quality was assessed using the Newcastle-Ottawa scale (observational cohort and version 2 (revision)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
